Literature DB >> 1663118

High-performance liquid chromatographic procedures for the determination of temafloxacin in biological matrices.

G R Granneman1, L L Varga.   

Abstract

A simple and precise high-performance liquid chromatographic procedure has been developed for the determination of temafloxacin and its trace level metabolites in biological matrices. Plasma samples are ultrafiltered after addition of an internal standard in a displacing reagent containing sodium dodecyl sulfate and acetonitrile. Plasma ultrafiltrates or diluted urines are chromatographed on a reversed-phase analytical column, using an ion-pair chromatographic mobile phase and fluorescence detection. The chromatographic system allows resolution and quantitation of temafloxacin's oxidative metabolites, which collectively account for less than 2% of the administered dose. The mean intra-assay coefficient of variation for determination of temafloxacin concentrations in plasma ranging from 0.05 to 10.0 micrograms/ml was 0.7%. The procedure was implemented at four laboratories for the analysis of over 12,000 samples from clinical studies. Inter-assay coefficients of variation estimated from routine analyses of quality control samples in these studies averaged 4% or lower for concentrations in the 0.15-10 micrograms/ml range. The limit of quantitation of the procedure is approximately 10 ng/ml; inter-assay coefficients of variation at 15 ng/ml averaged under 9%. Calibration curves were reproducible and highly linear, with correlation coefficients typically averaging over 0.9995. An alternative, more complex procedure, involving methylene chloride extraction, which extends the detection limits to below 1 ng/ml, is also described.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1663118     DOI: 10.1016/0378-4347(91)80353-e

Source DB:  PubMed          Journal:  J Chromatogr


  10 in total

1.  The relative bioavailability of temafloxacin administered through a nasogastric tube with and without enteral feeding.

Authors:  T J Lubowski; C H Nightingale; K Sweeney; R Quintiliani
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

2.  Effect of antacid medication on the pharmacokinetics of temafloxacin.

Authors:  G R Granneman; U Stephan; B Birner; F Sörgel; D Mukherjee
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

3.  Temafloxacin pharmacokinetics in subjects with normal and impaired renal function.

Authors:  G R Granneman; R Braeckman; J Kraut; S Shupien; J C Craft
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

4.  Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin.

Authors:  B A Mueller; D G Brierton; S R Abel; L Bowman
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

5.  Pharmacokinetics and pharmacodynamics of intravenous levofloxacin at 750 milligrams and various doses of metronidazole in healthy adult subjects.

Authors:  Kelly A Sprandel; Christopher A Schriever; Susan L Pendland; John P Quinn; Mark H Gotfried; Suzanne Hackett; Mary Beth Graham; Larry H Danziger; Keith A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

6.  Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults.

Authors:  Keith A Rodvold; Larry H Danziger; Mark H Gotfried
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

Review 7.  Pharmacokinetics of temafloxacin after multiple oral administration.

Authors:  G R Granneman
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

8.  The effect of food on the bioavailability of temafloxacin. A review of 3 studies.

Authors:  G R Granneman; D Mukherjee
Journal:  Clin Pharmacokinet       Date:  1992       Impact factor: 6.447

9.  Pharmacokinetics of temafloxacin in humans after multiple oral doses.

Authors:  G R Granneman; P Carpentier; P J Morrison; A G Pernet
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

10.  In vivo efficacy of trovafloxacin (CP-99,219), a new quinolone with extended activities against gram-positive pathogens, Streptococcus pneumoniae, and Bacteroides fragilis.

Authors:  A E Girard; D Girard; T D Gootz; J A Faiella; C R Cimochowski
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.